initi outperform pt
tool empir built one day
highest convict stock tool given acceler core thesi
go say think ross alway
like thermo fisher defens stock sinc
start cover decad ago keep score
equat o/p vs market vs healthcar
overal said went period like
stock post life deal hangov love stock pre
life deal current highest convict stock tool
thermo display acceler core growth one
strateg deal ever execut macro favor
valuat held back nonsens ye said nonsens
idea go challeng broadli channel base
extrapol small data point irrat us work
suggest littl traction
respect pthn believ acquir compani ahead
materi inflect growth similar time life
fei also present rich pipelin all-in add
low teen ep growth market cap put
rarifi air like possibl
continu execut would acknowledg share cheap
ebitda basi would point rel discount market
absolut price-to-earnings well yield justifi price target marc
pardon pun believ like outperform
given dynam see risk reward favor thu initi
share o/p rate
thing watch fei benefit core patheon underli trend
academ govern budget trajectori notabl us
debat pthn fei transform tmo core profil
threat channel busi long-term
precipic improv growth rate
valuat price target base dcf methodolog
contempl wacc termin ebitda multipl
equat perpetu growth rate pt
translat ebitda vs average
price-to-earnings basi translat vs average
downsid risk budgetari uncertainti us could limit pace
disburs nih govern fund pressur demand
outlook slowdown china relat demand given shift govern
polici materi depress key geograph driver core growth shift
semi materi relat growth fei due paus hiccup
macro outlook could de-rat analyt growth elev valuat
multipl rise rate depress activ result modest ep
upsid capit alloc new tax regul us could
upwardli pressur rate time albeit complex structur like
limit pace creep downward tick pharma demand due
increas scrutini drug price limit alloc dollar
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
initi outperform pt
tool empir built one day
last page report import disclosur regard stock report
tabl content
compani overview one stop shop life scienc
debat pthn fei transform tmo core profil
debat threat channel busi long-term
debat precipic improv growth rate
financi model consist dd compound
point differenti vs st
iv valuat risk price-to-earnings track growth
 conclus initi o/p best entri time
thermo fisher entif waltham one stop shop life
unriv world leader serv scienc
outsiz exposur recur revenu consum
rang instrument consum across biopharma
dx academ government industrial/appli end market
thesi pthn fei transact acceler underli
core growth acceler life exposur
rate valuat pt outperform pt
ebitda vs average
price-to-earnings vs average
risk facil custom challeng pthn
coupl macro slowdown limit growth upsid
china pharma appli key growth market
join compani
also join compani
mark stevenson evp yr
frederick lowri presid life solut
pthn/fei bring exposur high growth vertic electron microscopi fei biomanufactur pthn
grow biolog bigger part pipelin
high-growth tuck-in opportun
one-stop-shop need
cryo-em newest hottest tech hit life scienc
new vertic like add core deal massiv accret due synergi captur deal time fei pre cycl
includ share repo futur
bp
improv long-term core outlook like upwardli bia rel price-to-earnings
debat threat channel busi long-term
heighten concern tmo acad channel post report stanford use lab suppli
report threat academ laboratori channel
fear take lab overblown fail add valu custom outsid commod busi
aim use legaci busi suppli text book offer basic lab suppli commodit item glove etc
creat effici suppli chain ineffici market
credibl threat tmo rest tool academ lab channel
offer servic aftermarket item
took mani year offer tv instal hard imagin develop capabl servic lab
tmo scale scope
life oem compani sell scale abil sourc better
global busi effici suppli chain management much creat effici
tmo lab channel grown tmo corpor averag last yr time frame enter lab space
area see slight amount vulner commod product could lead slight growth headwind total revenu
overal threat moat around high valu products/servic
debat precipic improv growth rate
 growth lag despit help life deal
howev recent nih fund provid relief final
start see eu china help
broad improv like provid boost
north america consist w/ modest growth last
qs expect bn increas nih budget
continu momentum condit us
stabl grow modestli
 expect growth broad-bas
particular strength europ america due
academ market europ continu recov
us stabil
strong across geographi spend institut
focus biomed omic research
outsiz exposur high margin product mt tw off-set pharma normal
model summari point differenti vs street
swing factor fei pthn boost turnaround cadenc capit alloc
point differenti
bullish outlook core
pthn transact
ep st growth
manag level
despit up-tick
thermo compound machin nearli unriv cap rang
million except per share data fy end decemb organ organ product organ scienc organ organ gp less total product scienc op less ep share inc net inc price-to-earnings prem disc januari
valuat compel price-to-earnings basi given ldd growth outlook
ebitda multipl remain rich rel pariti market price-to-earnings attract given ep compound-annual-growth-rate
risk point favor risk reward profil outsid macro relat slowdown littl impact juggernaut
budgetari uncertainti us could limit pace disburs nih govern fund pressur demand outlook
slowdown china relat demand given shift govern polici materi depress key geograph driver core growth
shift semi materi relat growth fei due paus hiccup macro outlook could de-rat analyt growth
elev valuat multipl rise rate depress activ result modest ep upsid capit alloc
new tax regul us could upwardli pressur rate time albeit complex structur like limit pace creep
downward tick pharma demand due increas scrutini drug price limit alloc dollar go forward
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
tax rate
wacc base beta risk free rate cost debt
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total valu valu per perpetu growth valu enterpris enterpris valu januari
conclus initi outperform pt upsid
best class tsr continu w/ recent nonsens pull-back notabl buy opportun
go say think ross alway like thermo fisher
defens stock sinc start cover decad ago
keep score equat o/p vs market vs healthcar overal
said went period like stock post life deal hangov
love stock pre life deal current highest convict stock
thermo display acceler core growth one strateg deal
ever execut macro favor valuat held back nonsens
ye said nonsens idea go challeng broadli channel base
extrapol small data point irrat us work suggest littl traction
respect pthn believ acquir compani ahead materi inflect
growth similar time life fei also present rich pipelin
all-in add low teen ep growth market cap put
rarifi air like possibl continu execut
would acknowledg share cheap ebitda basi would point
rel discount market absolut price-to-earnings well yield justifi price target
marc pardon pun believ like outperform
given dynam see risk reward favor thu initi share o/p rate
thing watch fei benefit core pthn underli trend budget trajectori
pleas feel free reach question follow-up
medic suppli devic
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin januari et
analyst ross muken vijay kumar luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
